Dedicated Bifurcation Paclitaxel‐Eluting Stent BiOSS Expert® in the Treatment of Distal Left Main Stem Stenosis

Abstract

The dedicated bifurcation stent BiOSS Expert® proved to be a feasible device, with promising safety and long-term clinical effectiveness in the treatment of distal LMS stenosis.

Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial

“…The current results are similar to those recently reported by our group on LMS coronary artery treatment. 9 A lower LLL in the LMS subgroup suggests that this stent might be better suited for bifurcations with a greater difference in diameters between the MV and MB, such as the LMS coronary artery/LAD artery/left circumflex artery complex. This hypothesis is also supported by the rate of TLR in the LMS subgroup (BiOSS Expert vs rDES, 7.4% vs 11.1%; trend in favour of the BiOSS Expert); however, these observations require further confirmation from adequately powered randomized trials.…”

Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model

“…The first BiOSS ® stent was a bare metal one, but shortly after a paclitaxel‐eluting version was introduced into the market—the BiOSS Expert ® stent (CE Mark 2011). After acceptable results of the BiOSS Expert ® stent in two registries and in the randomized clinical trial POLBOS I (Polish Bifurcation Optimization Strategy), an option for improvement was to change paclitaxel into the olimus drug. The sirolimus was chosen, and the BiOSS LIM ® stent was developed (CE Mark 2012).…”

First‐in‐Man Study of Dedicated Bifurcation Sirolimus‐eluting Stent: 12‐month Results of BiOSS LIM® Registry

“…BiOSS LIM® is the next version of BiOSS® stent. The previous one (BiOSS Expert®) was also made of stainless steel (same design), but eluted paclitaxel . In BiOSS LIM® Registry the composite MACE rate was 11.7% (n = 7).…”